{
  "eval_set_id": "quickstart_eval",
  "name": "quickstart_eval",
  "description": null,
  "eval_cases": [
    {
      "eval_id": "simple",
      "conversation": [
        {
          "invocation_id": "e-ae5ccab6-6c5f-4d71-af28-cbe466f4bb35",
          "user_content": {
            "parts": [
              {
                "video_metadata": null,
                "thought": null,
                "inline_data": null,
                "file_data": null,
                "thought_signature": null,
                "code_execution_result": null,
                "executable_code": null,
                "function_call": null,
                "function_response": null,
                "text": "45-year-old female with invasive\nductal carcinoma, ER+/PR+/HER2-,\nBRCA1 mutation, T2N1M0"
              }
            ],
            "role": "user"
          },
          "final_response": {
            "parts": [
              {
                "video_metadata": null,
                "thought": null,
                "inline_data": null,
                "file_data": null,
                "thought_signature": "Cs8bAVSoXO61CxK-5QoaihFRovk-NUxxk9lYX2dOPDXRPeYD4pqv6qE31UCnnPsvxYJR688sunwH9mGJ4QIOfW6akze2JMMoQwW9YeBow3B1IClLN1IVswupu5Cs8J8EGRM7h_XsLY1xRcelfE0B21l3GlbL9HK7hr7TD11IERfzlGSWovW8GkrapIOKosDlIqKbTJ2BIae1pBxh6R9QZhSHu_S1SZAdDr0GMM_bkMyI23PUoNBa31rcwVKyFGZzR8--iBliCccRvGIKTApgoz27KyxyYzvVxnuZFXlrD7d4VjgXVM9KW_UMqnPFkDTGIkZD-8sRxeW5E0VOh88XG4gy61MoCLYHkegvr9bm23hc9vl14pg029lvlZ6FkIemb9yELe6qvtp-RD6In6T30655ZGXGWjfiQ_Hfmu0aBMq7TUiBr4OjQ_FUDwVA614AlTesv6VDtT4Ia_HapDDfAOe4w07ReKe4gjfpREKB8PrtKDWAzDSe9RWznRODDiWYgvP6KsTYuHkSf8lBd3DpqHapIdCuUfgUVrI-m6RZu1I66BDSDjeLHd6HaIuuMq-CAkxR9GHQhgCvY7hRUZ54S9wmPECwLMpxqoNzlJemZ9EL-WZu6UC9hMsSn2g6CmY7_CJM7Exuyeez8Z8DgCzmC6AQ0B78gJF8FgoZzIrRPSXyNnjRh0ZTcqHU1vm1IafkFRxuftepV99DzTZAqu2LkMG6mVF5rihFejGZtMhUn5Ls0CciyHJidnjdJHW1e0sSXPDQWM-EA7iSi0ufFLobvk2J35rhcZb8QY08MXeZlTw5VnQ_nFj5u2j0DpL1h-JUB6iaIQbOur2OyxtjCr13vkjMVjg4evcbiYc5F1bef4db3gXhOzrLTYGjvMM1HLcnRiKsf7zoH0XGDwp_zprBy8pts2qzRvg7_Diu60Fws1--cJLPAHm_m_YCcrONyHmJ7GOTiCDm7HX58GJxwguh-IeOlbn2Ak-zKpvp-3q0R3MQ6nrH7IOHj1gDqVgZoKTy6eCnLXQGwnJS3xze1ak1kZUizncI3LNaHw9cbM_WBWLVm30_wu3lRwibHKtFbfyXXJKzBJStrWQJgwO8c88Tk4eUl3_BjdGKaNoIj_k8kSgLwfS5J8PEHRQqW9cexCv9VNRt1Z4MX5ybmCQdcnmggUneEvNtuGhsHtipPtXl8RKCDscvHpmgd8d69eoySDMV-fn-gaNxosMs5QNO1pahPUtmTwd6VnjFGxonbsoX7V2iyBx41znEhQCg6BHu9zaVCbjqTanyknvk0BKpVPW6Dwt9aXCXIi1k6QSn5WKHWhOkKqu512Gi-K_kX-M7VLdN6Xb-P672yjtSMmBiJ2s9xAuispQpfb3ovxsEryfv_z2i7mcwJPW_5ceit3q8j7VzunP1VuJ60ObEZt1NpIvR3ZyL9aWThjhY3Y6bSD3FX6kKrtqYEh1C9XB_EPMKobcOfM4oikKWPK5A-X1OyjzaZ_ED0do4q0VfSwZgmYOWKVXHvtuQ1H0LOcslpkSbSJG8sDnMI0KGVNH8s6FqoBRfROqziLfg7I6TEd9b2HVcF9XuCoL75VsaJN-WLgIhuNOdZ069ODb1vBfG6sFZk1_pxRzGi3w_v9cYfyZqpsy7OKuWeV3FEV64AznHnubIrL2NmcY_FWLjT6dkoNJC5vWMZIRl1m8_9YjdEezPz5g_xHTxE1qmGI5lzHPjXqCbVMCI0TW1a-IpKSw1kkJhLbb7s5X-mC6jlY130AiYPLZINhZ7QKijMv-vNOvoIjB6Ye6m3HxedQObA48TtYNtsykv3HkebtmGQeLaaJspSdWbGZWrDO4YlCui7I_Eh59SifirJQ3zS8FViNzZSOHbVW3ZNNp-ZwrVY-T1AECeeA4MUxoEpcQYA9i0SSOs8RKRgc8y3S6WIUxc9EpqZixSvlJsK5xKLgkp7HNihOolm9kW6eYB4WDFPsoNYIMskogEzGDLMMXTQJboftoAzmiqgg-ZrwTP7rdkpk4UREvl8Cx28Iv1hKXwSKfqJJrO9cahtKkyYmTPAhayLTsrEPDd6JTJPEKM4BCbWs7qg81fOa1wPHQSTbsNYWVFREwggRfu3PLigwg582epsBWGyPrGaQT_TjERuwTF_LH7Cagd9b5x32FBAwY0t5r__yW1-e5YTNN6V-__VZdke9z6ndDpuIJ3Rw61PUcuJ1uYITIr9pjiH8e0tnILsmakvKQNxN3Pdoc2EZOJm4acNJO63WfIXzKfx2ObYDdr8S_CdAvaISNAYyjzjIMOg5tJFBNSfiIsVCtDDswlfgWVP5nJpcBN99Emcr8QP3SMhBolsgF45Xwpu-YswzNX5iwM6Pc1JnQ8ri85W-jp4zEivyAbcH18mtMukbVZGyDaPfSG3EaXy62t6w03hg1nH_5jy-4pAI5zmp75sW4cFiKhEsofM-5fiaVZQ59WdKhYiZyjTQdncc9yIYN1ydqyxAuuJd65qqf2gtd80O_YnTDolFLiILrO3NHNp6gBp4mKuwmcmEIWZrkwhKAvet6yJhwkI4k3XEygDyjWRIas-25y1AWQG6H3Me0EXJ9RK0nTgk7xcJ2DnvQgmp103GUM2-HeZHFkvqsTe3GKMs0cBeXuNAk0OFUM4p8tYq2o4J9xlGL9jau83nSh7ErUq6rPEjM0W4PeA0basYfkXNuyO1Nd-j0DLEO9_WCbAaU5zwApIQaIja-exwddJ0jD1c-jgROUBOju_NF6zxk5KTAgJxgfAwro4L57q3fhpWvi5MX4W9B2qD8S89nAQdnede-5_q_MFXLjskHw0_8Tv15fswfNwzDjtfO8wvyQpVepMhBNLXuQMMM8EA94jTLknoeoZMb5m86vorA9wYHjSWRIbPcHIV26_e9RjTB8TWMduaVwXb8CACCJj5wOJFw2SwSwKOS5MucPAXQ-EKB0qMkYQ0jKsyqaQL4zau9pkEIbuUFpxHulBdyKXb6M29EjRv1ZAhdFktAul0b_Pezuz3OIoDp7H6ArLWipyn5rb9nBwAcKXvivJX3-8APye6HGcEhX6nhpomYxKTpTrBJ3Jb-ClA_Qlq3_P-iYR3YjuUW_qzwKF2GVdAyHrWPlrXGG2x99BYDSTpV42kDmQHYYarfRNpuWtT68f6FtgGiqwwfWI1ZfQhGGpNZPUFwXRRl01bQsw4hn2Nr-C_dCxwupBO0PvXeluytn2D5pKWmx3ktRE68bwYIsLEcdXH7mxjrZfkvkghNCxZSkHbHiRPR48pXjfdQ40S3sIiT2DgFU0z9ibpoS63ilZZUEhgZQcgbuQ43M9KQCb-9fUjnlyD9zJdSVEpSmL3khl-3fP89UWBDv1Bu_Ut2N7sb5-WeQHNKS_A8musqgvX5zrmY8yrIMqNdZE8bWH31geOhTWb32vy5_sRF6F5HJt00z5QpN_i4OznlmSjDI6Vh0w2AAJrZ9l6Egi6K8IwQ0vssbsNCUqfqLddeNOEg6iGYL9Ko0QzRw1bVcojMyQEjyJ_TKSVN3wNxE57wJa8YXM-_uQu65GLBiapRPkVOPOywovIox1Pj_WPsC-hWYU3ZJUYCwjhlYH74s3ynnc8MbrELXscu-on2MGmwjLHyFl622hVtCcTqPm7ob10_tC5hyq3z480lAT_EOMmsbFIGw5L0IkHckOdguz79YgFWLdD9BqvBjzmrsHpCFoOMrMMz0pOBLl_N084GPOvdFLLcHo1OV8edXMluBz7CLBnTaXMfWeS5C3C21Bxj1ZqjrW0Y6ZBVb3T--AE55oHAeppNsewkj2O6eKtOvbC7UTMvnawqVbzCaWmgABhEUoy_Nl2HR_iuX-Jot6ALXvW3PMJ4IAiI3zITv_1HJpc2X89TAwKj5zN8sBj93nB8j9kZQDYklNC0kBUprFT5eoqXUMliNFNLI1IObCQMrj9J3kk-B-EojpUTeEbg4JYAF77rBzBguLTMGSCgbUU-5X7IOH_IJmXOqkGOd8pZJFpd4HXwokPYedIh4I_JyC2SPq6q6lD14s6V3wcGz6uMYtCi3QGznBKPppUErhLqdjFtZ-XePKdlgXKkJaqtkEYo_-LujUsJeJAVJc5SFHXIMfB8df9ant3YsIygHfRNazL67CtXIVbPQq2nIU6--U-5Xzme50Khn2xWSQK5XfrMWOqIpMfArp5FE9r0nU_h4C5BKB58xiiJz8deqACm-ks62bHsc5yFEf8qnGkwgJBVUiEGZpOzyOzfrHRltjwJ6XkGeZKvmYfG_NjVq2zdf1StvDc6YyVfEWVmx8yQMTyX3ClZpJboc62ewPMbvjbc2kbdeml-WdbOIQnE_CW4h5iopy_q43TeqRAENvfDwoI1mzqpS5hZQK28sUgvoHQ8VhCWf-YlyW286nhAv90OMTesTow3WHz4aimkcHg-PCmyTBbeMEwd4dvC_oQ3pBjVr7YfOnHY5bQXqIcZRk7Dlo9-luLS7JLanq6ibDZADV4etEwkACVQec-sNZ-EmfuRjnpkfajLgEf3-y4NBLZcjBG3TZchyse_C7J2JU86nmYs83myej_nTY-kq46UrS-P0h8hsf9yR-hv8dTQ-Sc9Ewjy9XmraNrmPFJnyx_c7w4H7jV2r8m16vQ2-IV_TLw4UPwM1BxtAqCO_Fh91WQ_dEkIqFbHqrvxOeLCMJd9TEt8WsaTxIht1BK9nxjB9BgJAU0Q1vQBmOvDVEZhZwsMTuw==",
                "code_execution_result": null,
                "executable_code": null,
                "function_call": null,
                "function_response": null,
                "text": "Analysis Results\nCase Analysis: ER+/PR+/HER2- Breast Cancer with Germline BRCA1 Mutation\n1. Case Summary\nThe patient is a 45-year-old female diagnosed with stage IIB (T2N1M0) invasive ductal carcinoma of the breast. The tumor is hormone receptor-positive (ER+/PR+) and HER2-negative. Germline genetic testing revealed a pathogenic `BRCA1` mutation. This combination of factors (hormone sensitivity, BRCA1-mutated status, and node-positive disease) defines a high-risk profile with distinct therapeutic vulnerabilities that can be targeted with specific agents. Treatment considerations will involve standard endocrine therapy, likely in combination with a CDK4/6 inhibitor, and a PARP inhibitor based on the germline mutation status.\n\n2. Actionable Events Analysis\n| EventType | Genetic/Clinical | Explanation | Targetable | Prognostic Value |\n| :--- | :--- | :--- | :--- | :--- |\n| **ER+/PR+ Status** | Clinical | The tumor expresses estrogen and progesterone receptors, indicating its growth is driven by hormones. | Yes, with endocrine therapies (e.g., AIs, SERMs) and CDK4/6 inhibitors. | Favorable, but risk of late recurrence exists. |\n| **Germline BRCA1 Mutation** | Genetic | A pathogenic mutation in the BRCA1 gene, leading to deficient homologous recombination repair (HRR) of DNA. | Yes, with PARP inhibitors (e.g., Olaparib, Talazoparib). | Both prognostic and predictive. Associated with higher-grade tumors but confers sensitivity to specific DNA-damaging agents and PARP inhibitors. |\n| **N1 (Node-Positive)** | Clinical | Cancer has spread to axillary lymph nodes, classifying the patient as having high-risk early-stage disease. | No, but it informs the aggressiveness of adjuvant therapy. | A key indicator of recurrence risk and prompts consideration for more intensive adjuvant treatment regimens. |\n\n***\n**Interpretation:**\nThis patient's cancer is defined by two primary targetable pathways. The ER+/PR+ status makes it susceptible to endocrine therapy, with CDK4/6 inhibitors being a standard addition in the high-risk setting to improve outcomes. The germline `BRCA1` mutation signifies a deficiency in DNA repair, creating a specific vulnerability to PARP inhibitors. The node-positive status elevates the patient's risk of recurrence, making her a candidate for more intensive adjuvant therapy, including consideration of the PARP inhibitor olaparib as established in the OlympiA trial.\n\n3. Treatment Options\n| Event | Treatment | Evidence | Evidence Summary | Previous Response | Warnings |\n| :--- | :--- | :--- | :--- | :--- | :--- |\n| **Germline BRCA1 Mutation** | Olaparib (adjuvant) | **OlympiA Trial** - Tuttle et al., 2021; Geyer et al., 2022 [NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2105215) [PMID: 34111394]; [Lancet Oncology](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00412-6/fulltext) [PMID: 35944577] | Adjuvant olaparib for 1 year in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer showed significantly improved invasive disease-free survival (IDFS) and overall survival (OS). | Not Applicable | Anemia, nausea, fatigue, neutropenia. Small risk of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). |\n| **ER+/PR+ Status** | Aromatase Inhibitor + Abemaciclib | **monarchE Trial** - Johnston et al., 2020 [JCO](https://ascopubs.org/doi/full/10.1200/JCO.20.02514) [PMID: 32955575] | In high-risk, node-positive, HR+/HER2- early breast cancer, adding 2 years of adjuvant abemaciclib to endocrine therapy significantly improved IDFS. | Not Applicable | Diarrhea is very common and can be dose-limiting. Neutropenia, fatigue, risk of venous thromboembolism (VTE). |\n| **ER+/PR+ Status** | Aromatase Inhibitor (AI) or Tamoxifen | **ATAC & BIG 1-98 Trials** - [Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61625-8/fulltext) [PMID: 19010018] | Landmark trials establishing the efficacy of AIs (anastrozole, letrozole) and tamoxifen in the adjuvant setting, reducing recurrence risk by ~50%. | Not Applicable | AI: Musculoskeletal pain, bone loss. Tamoxifen: Risk of endometrial cancer, VTE. |\n\n***\n**Clinical Perspective:**\nFor this patient, standard-of-care adjuvant treatment after completion of any necessary chemotherapy and local therapy (surgery/radiation) would involve endocrine therapy. Given her high-risk, node-positive status, the combination of an aromatase inhibitor (assuming she is postmenopausal or will undergo ovarian function suppression) and a CDK4/6 inhibitor like abemaciclib is a strong consideration, based on the monarchE trial data.\n\nSeparately, the OlympiA trial provides compelling evidence for 1 year of adjuvant olaparib. The patient meets the trial's eligibility criteria (node-positive disease). Current NCCN guidelines recommend considering olaparib for patients like this. The sequencing is important: olaparib is typically started after completion of chemotherapy and radiation and can be given concurrently with endocrine therapy. The decision between offering abemaciclib vs. olaparib, or how to sequence them, is a complex discussion as there is no direct comparative data. This should be reviewed by a multidisciplinary team, considering the patient's specific risk tolerance and potential toxicity profiles.\n\n4. Multi-Target Opportunities\n| Treatment Combination | Targeted Events | Evidence | Summary |\n| :--- | :--- | :--- | :--- |\n| **Aromatase Inhibitor + CDK4/6 Inhibitor (e.g., Abemaciclib)** | ER/PR Signaling, Cell Cycle Progression (CDK4/6) | **monarchE Trial** [PMID: 32955575] | This is a standard-of-care combination for high-risk HR+/HER2- early breast cancer. It dually blocks the hormonal driver of cancer growth and the cell cycle machinery, preventing proliferation. |\n| **Endocrine Therapy + Olaparib** | ER/PR Signaling, Deficient DNA Repair (BRCA1) | **OlympiA Trial** [PMID: 34111394] | In the OlympiA trial, olaparib was administered concurrently with standard endocrine therapy. This approach targets two independent vulnerabilities of the cancer cell simultaneously. |\n\n***\n**Analysis:**\nThe most evidence-based strategies for this patient involve leveraging both of her tumor's vulnerabilities. The combination of endocrine therapy with a CDK4/6 inhibitor is a well-established, guideline-endorsed approach for high-risk HR+ disease. The addition of a PARP inhibitor is also strongly supported by Level 1 evidence from the OlympiA trial.\n\nAs there is no direct evidence comparing (Endocrine Therapy + Abemaciclib) vs. (Endocrine Therapy + Olaparib) in a BRCA-mutated population, the decision requires careful clinical judgment. Many institutions would prioritize the PARP inhibitor given the profound survival benefit seen in OlympiA for this specific genetic subgroup. The combination of endocrine therapy and olaparib is well-tolerated and targets the foundational genetic vulnerability of this patient's cancer.\n\n***\n\n### Disclaimer\nThis report is for informational and research purposes only and is not a substitute for professional medical advice. The information provided should be reviewed and discussed by a qualified multidisciplinary tumor board and the patient's treating clinician to determine the most appropriate and individualized treatment plan."
              }
            ],
            "role": null
          },
          "intermediate_data": {
            "tool_uses": [],
            "intermediate_responses": []
          },
          "creation_timestamp": 1754690980.953209
        }
      ],
      "session_input": {
        "app_name": "capricorn_adk_agent",
        "user_id": "user",
        "state": {}
      },
      "creation_timestamp": 1754691028.8607569
    },
    {
      "eval_id": "complex",
      "conversation": [
        {
          "invocation_id": "e-637f01e8-f13d-412b-8823-fd562a9ce4c6",
          "user_content": {
            "parts": [
              {
                "video_metadata": null,
                "thought": null,
                "inline_data": null,
                "file_data": null,
                "thought_signature": null,
                "code_execution_result": null,
                "executable_code": null,
                "function_call": null,
                "function_response": null,
                "text": "A now almost 4-year-old female diagnosed with KMT2A-rearranged AML and CNS2 involvement exhibited refractory disease after NOPHO DBH AML 2012 protocol. Post- MEC and ADE, MRD remained at 35% and 53%. Vyxeos-clofarabine therapy reduced MRD to 18%. Third-line FLAG-Mylotarg lowered MRD to 3.5% (flow) and 1% (molecular). After a cord blood HSCT in December 2022, she relapsed 10 months later with 3% MRD and femoral extramedullary disease.\nAfter the iLTB discussion, in November 2023 the patient was enrolled in the SNDX5613 trial, receiving revumenib for three months, leading to a reduction in KMT2A MRD to 0.1% by PCR. Subsequently, the patient underwent a second allogeneic HSCT using cord blood with treosulfan, thiotepa, and fludarabine conditioning, followed by revumenib maintenance. In August 2024, 6.5 months after the second HSCT, the patient experienced a bone marrow relapse with 33% blasts. The patient is currently in very good clinical condition.\n\nDiagnostic tests:\n\nWES and RNAseq were performed on the 1st relapse sample showing KMT2A::MLLT3 fusion and NRAS (p.Gln61Lys) mutation.\n\nFlow cytometry from the current relapse showed positive CD33 and CD123.\n\nWES and RNAseq of the current relapse sample is pending."
              }
            ],
            "role": "user"
          },
          "final_response": {
            "parts": [
              {
                "video_metadata": null,
                "thought": null,
                "inline_data": null,
                "file_data": null,
                "thought_signature": "CpgnAVSoXO5hUIYpu9doLunNoyrQ24RAszf4lmTktzD9R41MsWcoUWCN8XFZqH9ujkSWFh339j-c9hwKqoho4Z6kxuPJ7zcgzQAyDDaERfkrwbSZhmxR9wT3ryTdEpY5vWdiuKeopea23oisXPhXgHh_y55_NhotLI5Z4hRKTw-e4BEZ0s73gGgYOYbo9vH3DAC1IDdOuwMVz01J4v3dmKlHL5slLlVNnvZK_3mwzA1NFMFAHoWUb6wUh63oCo3kksrfnNz_TKvL_snhcWQYK2OOnUFjC7sAJ_aLD3JXlIxqI0Tq7vnWG0mmuvUKJkq4NMSdIi5dRYc450HSRQISzYqr6EPGrJcc_cLr19iEv9H_jvLsBwGz6TrZZzKUd0Uc3y0NjE4M6FvSjYPReDUDqEYicu-RA0tIHpzPfp2bZrsiuUdygkHsDgWFY8pdf0GG3ljIVVJN-6hmaA_QVpqz0js3LAo-Tj-lt-AQp7vYR2L1DfJ-bbRDlP8HbyC_ILAAQtKs2oqKTooTc-AcUGG7LDpBVLjs2NCvRUKPrMGgCSIoKd1L2qouCQ6DGPOIX0oEQhDbNS3qNMQQHy26kdiJLAm4MiHdGufxR-BcAaO28_vv1ZX53hMCMDDayZq3SpqgvsMN9_RrW5eXTOydc97vKdR8SnQLRP9BBoa9eSxZy05OWb59EpPgJvmf_-3iJCHaSlhzrXg8Qud6M69tq09GzK1_RTgid99KnsRtVGWbQ872_JJI6_Bo2j3by0T9rPmlREVIExaJDLagTg1ZWintFooolVF4JGNEg2cJ7ksZqbFFnBagrntMf9Tba8P7G2jPDQ-7O9TA5LQil32QbGs5xtp5R9gduIhkQUMqAbkdqlfHyyWVpTSlzDCb3tF7OFutkCgEEPRtKT-8iZm1G27NRIkjHjCJQR4Uci_AzxnkZvu3_SO082skvrTto-1QZO8ornPacmkR0W4h08M9O_nvdXvZuInvUbi-4sfrhWCyiNe9jBAK7GkWgWqnOM36oJVk0stWPMVPkt56juothoKEQDkWwk5D-aFcgr4ei8aKAyEvdP3lDsl--in-wVd94zbGzlm1vScOVJEe2UkFwU8od6eppth7xbQeWnwk8Iaq7XFSzEkkcxfopkbpWYaZ27dHHCuTPoWiS54RUCQVzQkObquyhsVGdFyBT3-t5lFLQxVS854vDFt7BJgmfxzsaA40JGkIIgWhCyyBVtSpxo71pY-mF8khWd4Pep0dew-Of6Y-M5Yy232RoVYfLKmoDezwXZ-1UeYTU2TlPlaX1xTn_qqVNl2WcIpDp9uYPb_Qt8f2yXa5-EwXYdhoqnW1EohMIyQfAF4BmrquIc3obWa5LLGxjF-avZBdw9VEb_2mD7bk_aoGDmAuO2UPF5BOBBmpKV9sy5Xyaz2EKBy_4M7ewVjpDd8sPLIYpsDYPiEAPwOa0wawwdiuZmTNTEZ3im5TvcTrwqoqfs-_38e_PvVB7gJAX2MRz0eWBs1iUVlQmQvk-isB0fVyDyCuE8bL6qPmxczSykmb5FrZJzT_l7iMgJieQd_avhB6uiN0NmAvDjRqmNwvKjBUTYy8d1LygOUTBH0QmYD2TKfCdQMzD75LN6Eo5WecuA0xweC9aP4bZE_pfedxjODDNqFljJrx3dzTfQ3_6aL83zRNXwOIegpstg9c1BvAGegeS3vzXCXsluEKpNj4dWVbmLA20CgzRGCL2SJX2NChS7CRhgH87hZ7-riKBbfwsOYA55uxA2g-4YDyqRiIK7iTJRGO3mKUMp26EUE9mPvRaII5MwYtbUPBFe6lVxLYJv3ay9DtqKT4GXvn-T08ChwAGudfARvP69Yq0jewOP-ifd4sARh_VOjLKhKH1HSeXcTVwDyewwd5kiFYOxK8oBAJF24BJJBUZh-_L36E4_mDyj43zgs0B5I5Nob_9OLeQ6mZjNxQPcDbd4JMaZgL6OhnSkPzkbalI4JQbYgY6PxcmIcBC3v3hGAqFCt0iDpT8BKgFD63XrQQmioZPvVKVfnRRUHmQiVvjhxKOMY3crZqb3987LNEiMg0dksj4rfU12IRfY_KEMr3_M49dpawWqhngSUhm4mWXWnWYjBuC5h-uiRGODr722hVwamK2d61PNbRe_rTi-NSGIp6I5o-_phqXBu0OTkyf50_rkFMPb6hYejAldsvfUDgy-zKf10oJeeOk36gt8l1obUsStw94RRLygp7nf5By3irkQSoMHXz5ebCdo3TVUmeECWCb5l9HaqK0d7aAAm1ekpfk7qE25S1xDXRFjtoFA2Sd3MXFW7a0t9zCshQnzJdbNpkdjc6m7uLgxLYoBJMIIyZAB4rNFKEg2JPoft4ta5hsJvCLULUUhhNiZk1YOgMuVYSOpyBCkWM9F1fGoNl0ZBx5Y2vvsKzoBHQgraJxlOjzM-RljqQS9vUkpHdbUaabkLXa7bxlsgytGzcG38dfA1B-rjhaxkpaDn368rrQLZo0_m4cLZjfc58h8Lz1VzXMfniSMI_4nVZIZUgmqO8aoUxuTFWJRI36XQp4O9y4tNoMV2MMmCb9v3uD75x7NlZ-jpfVPvkfefLVZNZGbQQPlNuVF86KR7NJKLvfRMsJujnI1nCtIWYI4QmnL0qmIUR-aUq84DYwl6avdXQBz_1qlZKoPuHpanK5X385DX4BOOrRohVTudL8cSLVYpENlCJQ_EKtF5H4ziAZn97VP7lShqZA4-u11x_WSqizRE7VCkzyMlE9lGumqkg-ILhb7r2wvuyxB7q-ng_LmrpaH2ReHoLC7zYNrONkPV9gEwtENYAh5p14mcWXdYLEkaeWWKhprIQrAt0wzk4ARrT0OeYxEkWqjV9wC9R6uRg_jmyyZlb-9zydCowp43PHIczhad2SM2xDUs0ZdAj1BjPFG0U-mQ4wB4fQZKdKTbsmmmZbUQJmb0NatW8-MVsTLXnOR44V7fbQtoF__KbqVzR0vgqw39R_kKa3nPeP0ihy1d5ng_kTG_Um6N5AWFd86cXk2O5ySRy9mPLd27gm597apEmRBN53TlmE3OOTHu5yRKzJtfSNwFRNRIFbxF_PBMsReJ0CQ1Fo51bVCYDQat1mox6HhlVhIlXyjcBmSMIf2riVxtFSCRuF8kX3cqOwdEbJ0V7eHoa5OZqgbjjewKZKlIk4KEGxTju-cnu6VQIIKY60IvW6wbaLa96kBIhAAv5sdXH2z5lXnbPpF6ggrFyV7blJzC2ecA1k2N5lOVr1rqRZ1JT_OvEilSoSMOULLh4gfE02no2LQn7IP-03VcAS63vECjkaWfa4AWIy0UVtHEl6ewKjzl2mIC1v-IhJcFjiHNxwTzhDyoPO0Jh6gfAXu55HX48Mx_vI9CMp6iFpjxpx7U6Hlmwe-_xHr08-zK7H9Wf_tdZu8dmns-hnM8HLOIcNIFwuoMPHh1flpgaOve1pd2wsqxUsFmFs6AgupG-pWkwmdITzFjkHbRG057QmoPgcyWIjwkPZTZSzP5E_1sj_90Ja1E0Wr-pfqNnrtvZfP9AlZQeQJDRe10KaRjVlHJUQdJnisIXK19AbFAVOfLT9giXS474tzOJVCxTP1fEmx4uZ-F6Jx2u03MyCJI-5HFNHenZt7hch9wmLj0Ne_rGyhK4xVYP6ODt-IZKAE_qRy5ArQ5N6otePjcb5qXKd7VCY_tbxsRELl2B1x-lBJij92-cuQKVO1xXWMoZ64hnaPboASkxJg72SX8mlCCkMU_UeQlDydN4q2XlTuebN2ORtzfnO59x0TWJmV-xWS0Vi5oJwY7wcy5TU7idykSnRXEb-W7AOlk_Jb8U7sAn0FGGjNuAfGGDbPmspKTOajTeK8pNVngYMdSaElYVB3M4BoCbJzidyYXFS0KZYqoAkK0X6MxE57Se7JaQkJHk6fjSoKCCUlTUO-332yVaMAOTn9a8rO8fCwzioi9btpwGjVy2g8heo0uubKe5ddiG8h_HYLY3TsAkbdNMf_qxM2ws-UB8V7GQX7L1zYOrLhvyZ0BzDNByqv8LcGU3HsNsdAxAlx7gtzJ3NVInFNjh7WcKZSg1udNjpE3MHj4HHDloZNtLmjuVmLFNJ1tNQwlx7RPHFWcmXzaqFPsbYOOiULI-YVWJJwt6GvVVfS3RFqZd5kAIK_1q-a92kfaYW1sku1uIEonlf9iaS5gyK8dyehJOQEhNL5t_m6jut-3aj5zbJnE7gBXXXxXvUSTbe6gzy7IeRaIxApTguPUWyVjqsstXXbA5Rm9DSocrkRe-0RI93-G8Rj7uRv1gg7xG0eRtjwYqTFZe1aVqehGYIabCX2wHWtcHIz6yoEYHzlf9duSaQNzxs6u9qOMjQ843nsEfqO4mWCp-hBZy7oleKeN9ky_MEnn42g5doOJ7OuOcTMNROGJr7Q28f1R1Sj_Su72kCeIx8kddK546ugQ0XLoX5jNFpqJeTHTVfVz0RTm1PF6oMGZaxCKAo6pyPfuVrR-yK4gkaJREkYMJKvOyXdGi3vo-RWfHhExzuU0uJXMYCPTTQpkgYGG_REiD3RyzeE6E-KBygof3ZnYNdEo4Eq3hnT5563SRGnllX9LQot3tWPeka7UfzM7Vkttfr50OFBC-KLBU4aRSubFQM-v1Mlh1S5IOUAszB7uB2lDcI16_h4xYSRIbcxSSHHHJ0vo2eY5RqL4-7sHz5fqrY2Ft82G1LU_knt4kNij-BzgxAkUSdPZq2Gq4qwN7cK368DDDWSbXxYreOPQOmm5lQcjVIBw6S9LXqlI20q18BLuAveO0RHkvZzguQofmwP0YSJ7EVKMQy185WXJrcP5MTtEC-9090BtXBquwXoiygJGXzsmVTsk-lsJ2K1wIsb6kq3na5M0Sn5411cHOL5S-GjpM375PTw6f5X4ErjJV4Hr__WJ4R9GdfyodcdlLiit8imMZ4Ztc7o3t54lHCVK7ImHD2ttkGlUbeXG_xfESui43ki_RVbC3zD_nDQ0WBKH9jvyy0PU8D1xC7K5p8Z4tWNYdW1Kn5k7VVA7fwVL_4E-gjzNaOXXSx2iWZj9gT6A2jAhycjZsIeL0rK7qVt6rrh5txyn-AUcL2gub7UJCnFDf36F9O6OdOj-GgF8aKsQYKDyHfdzrAjQekrXytRoJ7eKW3Y-AdkhUbhI-uMA9XYJ8F2qVjKEfcgt781SdkZZ_jD9wA52TC0pxovUJyuHeYX32w1ZoeBkA7ebSauSIBNHvRAM-_6Xsc-ae51_SQSpbblKnkQAPyzu4TyC4VstkXGKjp3WBT6hWoNjgMvEsg3NLzGZnFsnTHWRkEflt7GV-rL_Ldl6enyEwRsi0oJ8bPckN_jYyB6C-Y4bMVCN7hh9NAGfkssrYvpUHhwSTeRDXvj2aoDAsT0MOEjZV3DQrknu1ca67wan3X0pIX4EUm-IFjaVlxCe5wA-YqkXsDZ4_iomuxiogxfEN7zPh3x9JpCx7xNOi4AzfqI2UAJdqFUv3GHEb8ccUWTev7ZiMAePNBIHS9TGUqB1xfnlBIbHQWua218xF3S8sJZxiDT5W5eLDTrqbZ86qTtJxTKXocq9agP5e4Si0MAtlDOkHwQiIJb46rUIPRoVPVad61j_7kzTB2xXmojOzvEqDzv93ju3sU-19xvxKzu3ewxMs0EazTy7GC1fSCUf7suFNALjheIrazXe1TRbJom9ArCwlpacZvOqm0Y2kO3cDBvPl37MQH4nu7lBHYsv-gzKwsPTBFBE37-s9gfjZo-u8B1K1XHIJnPkGOwiGTiCT5YpRLx8iMDGW9mLxWdG6YzP8vqZVCsKXjBQJMVkGdjjHUo5FZUlYRxJgOKMwRqFKJwH2WC6sUiw6UjUaC4tSiH-AIHhAmr8m7YO1bsmtjcUKwKEoMjtjrVeXC7mDYB1-UgbFPXRQaev32sGxJ1qT7OQel9-TFI6OgrsvJfxZbNdz8K6y1_gbc00szeE0UyxNTT419M-S7zLQmUm5BaVP3t9rT4vvK67Dp5ovxMKAqUDNeR_kRziV7iql16pUaXI8ftBoYPihuSOGWdAN06NLpf3TxUaQEdG0uoRExWDub62VtuHzexqoawqMeKgmFMBmycCqnDTJXusgOttiBnd8Z8pBs7BIgV6AHYlji5IsdEEGEgWBI4JBwdn1C-EcDcTEw1u3WQqL2fdP5SzDLWxA6_gRAry1DNDMYOQ6NqssfpvBrlHJU5AffWLzBPceOLr9EhM6etStgEKc0TsuqDE2Kgas_v7yNr2LzKAgm8QMthhJ4yT0UsEkY5XaBTpQJc2L1k2cEx2Odvq2Cs7NqFFZoC6nFtzHpC4gjT9_DrlJKmVCxSWphYpRT7l2bv8KbG-oGH6FDTctLXcK1cv60uNYyeDGt01vnnzQSHe5sYWR6RYC8CExZAaW-7MpCfwZi16QaaPLN671HK_NFp4FzC5val-ZVIA93OHYp9rjdIWDhgxASkF8tVGHHUK4OojfvS1VeiYuXp6LJ_WVx9T6LS0mmql1m-QBUglLkbls8aPFq65rd7QYBBQohA1dOesqwi6FdVIpi6Z6W7LSbTqyinwN964j-aP8XMmPjP1Ph8TtBXf6lf6unlMmlyv7O963ualM-q3WSnf5bX5T1bdgXo403m1bN4pXyfe7jD0rKICqeRNJoAJIz9WOSDW6mTARvUOOaYFvRKN6PazAox7qbjNO",
                "code_execution_result": null,
                "executable_code": null,
                "function_call": null,
                "function_response": null,
                "text": "Analysis Results\nCase Analysis: Relapsed/Refractory KMT2A::MLLT3, NRAS-mutated AML\n1. Case Summary\nThe patient is a 4-year-old female with a history of highly refractory *KMT2A*-rearranged (KMT2A::MLLT3) acute myeloid leukemia (AML) with CNS2 involvement at diagnosis. She demonstrated minimal response to multiple lines of intensive chemotherapy (NOPHO, MEC, ADE, Vyxeos-clofarabine, FLAG-Mylotarg). Following a first cord blood HSCT, she relapsed at 10 months with evidence of a cooperating *NRAS* (p.Gln61Lys) mutation. She was subsequently enrolled in a clinical trial with the menin inhibitor revumenib, achieving a deep molecular response before proceeding to a second allogeneic HSCT with revumenib maintenance. Despite this, she experienced a bone marrow relapse 6.5 months post-transplant, with 33% blasts that are positive for CD33 and CD123. The case represents a significant clinical challenge due to relapse on a highly targeted therapy, driven by a known resistance pathway.\n\n2. Actionable Events Analysis\n| EventType | Genetic/Clinical | Explanation | Targetable | Prognostic Value |\n| :--- | :--- | :--- | :--- | :--- |\n| **KMT2A::MLLT3 fusion** | Genetic | The primary leukemogenic driver of the AML, known to be sensitive to menin inhibitors. | Yes (Menin inhibitors). | Poor; associated with aggressive disease and high relapse rates. |\n| **NRAS (p.Gln61Lys) mutation** | Genetic | A common cooperating mutation that activates the RAS/MAPK pathway. It is a known mechanism of resistance to menin inhibitors. | Yes (MEK inhibitors, investigational). | Poor; confers a proliferative advantage and can drive resistance to targeted therapies. |\n| **Relapse on Revumenib** | Clinical | The patient relapsed while on maintenance revumenib, indicating acquired or secondary resistance. | Yes, by bypassing or overcoming the resistance mechanism. | Poor; signifies aggressive biology and exhaustion of a key targeted therapy class as monotherapy. |\n| **CD33 Expression** | Clinical | Surface antigen present on myeloblasts. | Yes (ADCs, CAR-T). | Target for therapy. Not a strong independent prognostic factor. |\n| **CD123 Expression** | Clinical | Surface antigen highly expressed on leukemic stem cells and blasts. | Yes (ADCs, Bi-specifics, CAR-T). | Target for therapy. High expression can be associated with poor prognosis. |\n\n**Interpretation:**\nThe constellation of findings points to a disease driven by the *KMT2A::MLLT3* fusion with the *NRAS* mutation acting as a critical cooperating event and the primary driver of resistance to menin inhibition. Relapse on revumenib was a predictable outcome given that RAS/MAPK pathway activation is a well-described escape mechanism that bypasses menin-KMT2A interaction blockade. Therefore, any future therapeutic strategy must address both the primary KMT2A driver and this parallel oncogenic signaling pathway. The expression of CD33 and CD123 provides additional, independent targets for immunotherapy, which may be crucial in a patient with a history of resistance to both chemotherapy and targeted agents. The pending genomic data from the current relapse is critical to confirm the stability of these drivers and rule out new mutations, such as in the menin-binding pocket of KMT2A.\n\n3. Treatment Options\n| Event | Treatment | Evidence | Evidence Summary | Previous Response | Warnings |\n| :--- | :--- | :--- | :--- | :--- | :--- |\n| **KMT2A::MLLT3 + NRAS** | **Revumenib + MEK Inhibitor** (e.g., Trametinib) | Kwon et al., 2023 [PMID: 37858348] | Preclinical models show this combination overcomes RAS-mediated resistance to menin inhibitors, demonstrating synergistic anti-leukemic activity and improved survival. | N/A (Combination is novel) | Potential for overlapping toxicities (e.g., rash, GI toxicity, cardiac). Requires careful monitoring in a clinical trial setting. |\n| **KMT2A::MLLT3 (BCL-2 Dependency)** | **Venetoclax + Chemotherapy** (e.g., Fludarabine/Cytarabine) | Conti et al., 2021 [PMID: 34133919] | In pediatric R/R AML, venetoclax combinations have shown high rates of CR (70-100%), particularly in KMT2A-r AML, which is known to be highly BCL-2 dependent. | N/A | Myelosuppression, tumor lysis syndrome (TLS). Patient has been heavily pre-treated, increasing risk of prolonged cytopenias. |\n| **CD123 Expression** | **Pivekimab Sunirine (IMGN632)** | Daver et al., 2024 [PMID: 38232616] | This CD123-targeted antibody-drug conjugate (ADC) showed a 29% CR/CRh rate in R/R AML patients, with a favorable safety profile and notable activity in KMT2A-r disease. | N/A | Myelosuppression, infusion-related reactions. Lower rates of veno-occlusive disease (VOD) compared to other ADCs. |\n| **CD33 Expression** | **PRGN-3006 (UltraCAR-T)** | Gourley et al., 2023 [ASH Abstract 220] | This non-viral, gene-edited CAR-T therapy showed a 50% CR/CRi rate in a Phase 1b study of R/R AML. Responses were seen in KMT2A-r patients and the therapy was well-tolerated. | Partially (Prior Mylotarg) | Cytokine Release Syndrome (CRS), neurotoxicity, myelosuppression. Requires specialized center. |\n| **CD123 Expression** | **Flotetuzumab** | Aldoss et al., 2023 [PMID: 36477174] | This CD123xCD3 DART molecule showed a 32.1% CR/CRh rate in primary refractory AML. Efficacy is linked to an immune-inflamed microenvironment. | N/A | High rates of CRS (Grade ≥3 in 29%), requiring step-up dosing and intensive supportive care. |\n\n**Clinical Perspective:**\nGiven the relapse on revumenib monotherapy, a single-agent approach is unlikely to be successful. The most biologically rational strategy is a combination therapy that directly addresses the known resistance mechanism. The combination of a menin inhibitor with a MEK inhibitor is strongly supported by preclinical data and directly targets the KMT2A and NRAS drivers in this patient. This should be pursued as the top option, ideally within a clinical trial.\n\nA venetoclax-based combination is another excellent choice, leveraging the known BCL-2 dependency of *KMT2A-r* AML. This could be effective in inducing remission, though the patient's extensive prior therapy raises concerns for hematologic toxicity.\n\nThe novel immunotherapies targeting CD123 (Pivekimab) or CD33 (PRGN-3006 CAR-T) represent powerful, non-cross-resistant options. Pivekimab appears well-tolerated and could be an effective bridge. Cellular therapy like PRGN-3006 offers the potential for a deep, durable response but requires significant logistical planning and toxicity management. A sequential approach, such as achieving MRD negativity with a combination therapy followed by immunotherapy or a third HSCT, may be the ultimate path toward long-term survival.\n\n4. Multi-Target Opportunities\n| Treatment Combination | Targeted Events | Evidence | Summary |\n| :--- | :--- | :--- | :--- |\n| **Revumenib + Trametinib** | KMT2A::MLLT3, NRAS | Kwon et al., 2023 [PMID: 37858348] | This is a rational, synergistic combination designed to restore sensitivity to menin inhibition by blocking the parallel RAS/MAPK survival pathway. Clinical trials are emerging. |\n| **Revumenib + Venetoclax** | KMT2A::MLLT3, BCL-2 | Rational combination based on independent mechanisms. | *KMT2A-r* AML is sensitive to both menin and BCL-2 inhibitors. This dual targeting of core dependencies is a promising strategy being explored in clinical trials (e.g., NCT05731557). |\n| **Venetoclax + Pivekimab Sunirine** | BCL-2, CD123 | Investigational Combination | Combines a core metabolic dependency inhibitor (Venetoclax) with a targeted immunotherapy (CD123 ADC) to attack the leukemia via two distinct and non-cross-resistant mechanisms. |\n\n**Analysis:**\nThe most compelling strategy for this patient is the combination of revumenib and a MEK inhibitor like trametinib. This approach is mechanistically tailored to her specific tumor biology—targeting both the primary driver and the identified resistance pathway. Evidence, while still preclinical, is strong and directly applicable. A combination of revumenib and venetoclax is also highly attractive, as it targets two fundamental vulnerabilities of *KMT2A-r* leukemia. Combining venetoclax with a novel immunotherapy like pivekimab could also be considered to maximize cytotoxicity through different mechanisms, potentially reducing the risk of developing further resistance. Enrollment in a clinical trial exploring one of these combinations should be prioritized.\n\n## References\n1.  Aldoss, I., Uy, G. L., Vey, N., et al. (2023). Flotetuzumab as salvage therapy for primary induction failure and early relapse acute myeloid leukemia. *Blood*, 141(11), 1389-1393. [PMID: 36477174](https://pubmed.ncbi.nlm.nih.gov/36477174/)\n2.  Conti, E., Riva, L., Vinti, L., et al. (2021). Venetoclax is effective in high-risk relapsed/refractory pediatric acute myeloid leukemia. *Blood Advances*, 5(12), 2695-2699. [PMID: 34133919](https://pubmed.ncbi.nlm.nih.gov/34133919/)\n3.  Daver, N., Montesinos, P., DeAngelo, D. J., et al. (2024). Pivekimab sunirine (IMGN632), a CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia: results of the CADENZA study. *Journal of Clinical Oncology*, 42(6), 696-707. [PMID: 38232616](https://pubmed.ncbi.nlm.nih.gov/38232616/)\n4.  Gourley, M., et al. (2023). A Phase 1b Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (MDS). *Blood*, 142(Supplement 1), 220. [ASH Abstract 220](https://ash.confex.com/ash/2023/webprogram/Paper180295.html)\n5.  Kwon, H. S., Huang, Y., Gogliotti, R. D., et al. (2023). RAS/MAPK pathway mutations are recurrent genetic events in KMT2Ar AML and confer resistance to menin inhibition. *Blood*, 142(16), 1364-1370. [PMID: 37858348](https://pubmed.ncbi.nlm.nih.gov/37858348/)\n\n***\n\n**Disclaimer:** This report is for informational and research purposes only and is not a substitute for professional medical advice. The information provided should be reviewed and discussed by a multidisciplinary tumor board and the patient's qualified clinical team, who are responsible for all treatment decisions."
              }
            ],
            "role": null
          },
          "intermediate_data": {
            "tool_uses": [
              {
                "id": "adk-8f7304ca-1865-4a2d-ad41-092046c77a4f",
                "args": {
                  "request": "Review treatment strategies for a 4-year-old with KMT2A::MLLT3 and NRAS G61K AML who has relapsed on revumenib maintenance therapy post-second HSCT. The blasts are CD33+ and CD123+. Focus on:\n1.  Preclinical and clinical evidence for combining menin inhibitors with MEK inhibitors to target both alterations and overcome resistance.\n2.  The role and efficacy of venetoclax-based combinations in this subtype of AML.\n3.  Clinical data on novel CD33 and CD123-targeted immunotherapies relevant to pediatric relapsed/refractory AML."
                },
                "name": "literature_review_coordinator"
              }
            ],
            "intermediate_responses": []
          },
          "creation_timestamp": 1754691903.835339
        }
      ],
      "session_input": {
        "app_name": "capricorn_adk_agent",
        "user_id": "user",
        "state": {}
      },
      "creation_timestamp": 1754692587.0072331
    },
    {
      "eval_id": "complex_2",
      "conversation": [
        {
          "invocation_id": "e-e50358b9-2442-4a86-81ca-829f02766625",
          "user_content": {
            "parts": [
              {
                "video_metadata": null,
                "thought": null,
                "inline_data": null,
                "file_data": null,
                "thought_signature": null,
                "code_execution_result": null,
                "executable_code": null,
                "function_call": null,
                "function_response": null,
                "text": "A now almost 4-year-old female diagnosed with KMT2A-rearranged AML and CNS2 involvement exhibited refractory disease after NOPHO DBH AML 2012 protocol. Post- MEC and ADE, MRD remained at 35% and 53%. Vyxeos-clofarabine therapy reduced MRD to 18%. Third-line FLAG-Mylotarg lowered MRD to 3.5% (flow) and 1% (molecular). After a cord blood HSCT in December 2022, she relapsed 10 months later with 3% MRD and femoral extramedullary disease.\nAfter the iLTB discussion, in November 2023 the patient was enrolled in the SNDX5613 trial, receiving revumenib for three months, leading to a reduction in KMT2A MRD to 0.1% by PCR. Subsequently, the patient underwent a second allogeneic HSCT using cord blood with treosulfan, thiotepa, and fludarabine conditioning, followed by revumenib maintenance. In August 2024, 6.5 months after the second HSCT, the patient experienced a bone marrow relapse with 33% blasts. The patient is currently in very good clinical condition.\n\nDiagnostic tests:\n\nWES and RNAseq were performed on the 1st relapse sample showing KMT2A::MLLT3 fusion and NRAS (p.Gln61Lys) mutation.\n\nFlow cytometry from the current relapse showed positive CD33 and CD123.\n\nWES and RNAseq of the current relapse sample is pending."
              }
            ],
            "role": "user"
          },
          "final_response": {
            "parts": [
              {
                "video_metadata": null,
                "thought": null,
                "inline_data": null,
                "file_data": null,
                "thought_signature": "CuwnAVSoXO7KhOxBiPTUzRQ0KxNRFnDAgLi2aAyoWgttUqIOA_KZaNUBS-irzg2lWvnSaTxQWtyWuQl8dHmNzVrn8cHHQ1uPxAp_ZKhwUkY3sBUOvgxBbvGn_xUY_Zids9w6dlAka58wofZvH1FOjIoX54S2lrPN-lmkUV1AX8vpU427_ETBJeoNnreeXhzjsvu5TdP6WxSXuN6avns7B2rtn1cfSkWAAANoKHPdOs14LY9JbD51dDPFkAXPC58JyJ97wTvCd3XYzNrQAGY3faSc6yiNWiygk5mXnzEe9ODs8tfJ00JDSlV7OXdn00kithGvZeOmPOrRCFryfGceSv9GQE_3Ygkjs7IKx91ps_KGmcRj2LkleQxqGOJaMCbjiPMBYCjitFkSrkSQLfUcqGld1jwBg6fGD4mR_gtFHtSpSalkdELGD90a_PuQAagRL3e0_x-wtCm8C7Vw18Bhlacq2ntVAdIs6PfVmx-BDDlGBh6ChZqEdLPlU2TTkI5VJsC3Fa2bsTfmLaYos-_BUs6XXMjnKeyVbaE2Zp7xTytMT-RVd7vNU5mVo93rDbhsrZ9jpVZ8Q-x7FQlpZybmWdDUE-n1YVL9vl-2Jz7eLSgEf3Cff0LxTHm1klgLs6Qq1PEK4iZ_n5d4kWjX7pZcYWtPfvoTsGGIoCU8sXQXgP5V4Gy06bsba2oxIaI87t6D3d6snSSEw39YOubEN_mZ-Jmf3EIXxHvDDIfime6qn0UhMO2aRxgufsmCLMjGAsRcfJ8bkXtvLhM42T-XOmk_fkIVF9Chai1d2VFUG2YEmhPOjkx5ZrMd5Bn5wNR--MMVfNw0QJTFYKLqExgY4cvHHDMkqj309D-3gYXKIZOSAIs1ArWaS_fXZ6TFMeR-F6xha7kPOBWXRnP9NdOU_cYMuQIqBdQ4HRa4nl-CPZmZAJhRYasu7xRIKCyM86VwI6J3TG5HOFuiH1esTGm2SHPitHtBBpyBTMeCa9BRB3SO4mDu9OXYSgaNro0lffpKGDgGbP3S0W1PoWQaAD2APcbdp-yE2VwMOgdRv-kBVHKHnvuUcVnBGSS654WBVoS6OUM1xVCnyk0dZHnopGUgmpJj8dNQVwu8Kz7MV_DyeBJ1IhWpJSM5fKZMtp0GCBHX13JZaH8aycZ9zQnuTau76dhSZ_swttJuHHPGTqbfbNjHWfF0aZydn7zED7f1LN_javZmAtX3XzZ0hX-eldXWzO77xMzqW6eB-AAax9_C7kFlL3BQs5xrdpXTvDGcyjb7FPFyBeNBTUwtTyT7U54XIQhHWxizVgmXJrtJ9oHAGLYi1RfcN7utnIEAYSTPnRUOlLc6hO6_w7gqJC49jXt7rVhBX3YiqjGVCn4SwXSx31IX2tVkUONeJL2oHhrdzwFJFsQkAnUxWebtHQm5qPFDFqGTHUW4rwdgMDjK5xBTXLH4AwDEL7mNT6xF0w7J2RERaQYAxBi7dlgQQ8lIe70bWwMA9TJU_9tmcjLtSwyqIB7NKC0-0d4we2X0ynfKHyiZKPaAejgE_dKu6UKzswhBL3xjIrbIfpYND5YlakUHjfbEJIw6Mj8jwSDDlciCx6s4ZiP3t2ocIP9mRX13H-HC847KMvppOwjKBN0J9_bPuQQbh4QHuO5dmXAGgDXOJkTLcg4U_7vn9h1BjkghxA7SREnW7zF7AaTwkvebFYX71Lb05sTCUzUMpCTNljxuVhb-mIQUWguJhET9dq2AAfenjdhCt-hUpO4LrLWAd53HCUsxWxAeJUGUhegrohBpqUKETSJMTYS_-nyUubXcgUxCnMuDUMyqFrdl1woCuGGaTjfMguzovhXKK3uh81np4qxXmpY4MmnyaoGatT9SeiNYpz_aoOJPT7-GKOeb-C8IPqM9L48KHJivc9JNX0MXajznfTsl_rDCO5x5vxPRGvY3negEhRbU3FYykCs-6_xQq3zEgYxxpkniyy2JIqFKOnoJlQXc3eTBAzvy8OC1BnFW8xfuy91bmNQQhNDVtE2iTAw-4OHOlfVzAWd5qhubnV8krlmVqFFNwIpEvTW47fANSRjCdw7gHJH0vGs5zj2xLY1kOY_42aS5IkEvZnzbzS5I9PPXUutogKJsjS6BaGVhMpXVeT4JJkeBJrdWOkSxXzatpX6VVdYAIkwl4PqtnpeeKv9v1sWHjMxDQ7hpeGKUzd38VvKKgNImbqW7Ukm0S_oCp60d1L8JuRgM9MBq03iSx6hUCbLY46SFHM7tadMS64G7uxPjQEYnUqDB6pjznj6tRcHEDmNJ1v-YDjg0AZgGg7RBYUNLfWnVPoYow7ax7lpu4XC1kpdn24WWLSEgWtJFZz8hQnVdB2WPJLNQVEtt8-11rKMaabhBnzh--TFM3ISYx8OZDxAtoVhAgd2X3mkqQbpbiLMosXs1k5u52DWPyRJoPyBl7c4MutpARRuHakIsBwlvsE3KpIKRV-lZSKX_8RNjC8AsKZAis6mHTtH3CAfKRaa1Ntg3BkKtqGhLQ5xucNrzKWWHeDwBR_4Y8s1O-8lv5AcBWWi1k4Yaaysjp2fwBObZxwb_9el_WADvx7TQRKWM9s2SbLQ891b4OKbQw8pd6Vy3d7PmBkT31o7ttZI2EHJZa08AVbtQ91uZMggowMI9iE8QwQ7sHF3VbWq7l1eWtUSgJjHV5eXs7G0JgKrByel7M81Qhbzz95S4nn3kAPrSYpl-SWb_W-qpoK0yGKqlUtNG_J8XRq9E-puTwBSLILmrlioWHD-LPoNFZ975g9B6doFsqrwIYMQhu10HU9Ib5vY_zARj2U7xx9p4rkocCwQPHVxDAs0rd8vM4frgUutWOIQ_S97GCN0pt4ewz8VIn2Q1FDo1tf5UUzr7r2Yy11eJDeV5lnFUoTdoqcHoz1YerbEBln9OrM1whAzklmKUHM2_SICR5CN0g4tEALw1_EU6NG2DjNd4-dg93ja0UD8PYedjjMZC6hshpb1jdO79KMgpEEmzokB4Uvjli7Xo9Xx9YSobKSeCOUPKcPByMVd--9foRB92UgaH-D0s1lMxOPc5iwMglp0xAok_zogAg18KGBe9GhCpN7XCYTKc_Oy8XcFYde_PmbhSaqQGvpRnjBanbXH2XnNJUgrqgL_Lg0T-hGmw8PmKQvivXW72RdFuFH2OZf50FL30EjYLofWSPoRApG83SB1SeMyJsnoLF4pMWKXP1nkJ05wuOQQXwyh_T66JEXg6e--jzEnLdRzLi7TXHNAAP8UX62yxR0qTlzHoFTPididd0cvnyKLgnCVhOmlEKnM8v26qUIRxxYND8U8xBIWtLQ8-ILP0Hkis0lBjsJBo6E5foCAHtM_UUn_WKb8ghdHkqMEcE75k5rd2s2WW0NzvWXMNdatCvX-ObVReMpVJr3lltcCsQNjOlSJnvB-aIzf_pxyXHRypzZshYuqBI8A1_JVkgJJ4gRfnObiNFRJPwdBhQdKzRerB4qUEoSRQr1tJICvcQHOIyKHBlxGliKxi6jOfDqOHxiEsYJFScmO9elhRX4gyMiurv-az8ysuOA0eWDa-T8XEGXk6DCIiv3DHSX7esnCZNTcoy50qJSbR9jfjndv9_T1o3FsZ-mrpcL4CgSwL6vwbOMRrtEAMf8nSkE5NMIgFOfclYjQIlHFpb2kVy2NHeWOIawui_x41pwfUQrdt7mJQT2hV1nK7Hryb17Tl7YQALSjdpkQSjb2S6KUIlz8SgddmMXA6fVw2lVI4MbADp5J1jsfJnsz77KveAaEJA4y51wemQmgU2j2YZy2s7L2QWVOiZCSTQrrkY9mmmyh9IfzrCViduCDzrFjcC5mWVQhsYRhVvdp2bViIFycLGJukdWKwvAjH-A3CHDC3YnY3sk_pypUvCr9mA3kLm4Ddql0kZ6gsqP1OZym6XWLiOXKodzj0uQyJuM1RzTO5RBRHH9M1I0BHEzf7LsdeZNh_aZpons20UNFw_t_WyEV447pspvr8xPIEYwhsCNqExGqqy6yg-kJp6ay7U4XRBdstTy7xCiMOmSMIKMqO4pNZo1rA33ETfbXAViwIZK78TqNkhI62wsA75SvzQ7edN7DyQPxM21_6zDtHMORY0EUzVLYN7rhpC5GfaL_GgQ42kWuLM-U3WCb40llJHJzF47UUcvXFWoIefrNgv2UG0lvvnphKjWnjQu2K3L0tNpAUIJEYKc27UVhQGACwi0mUIxYdsHIZqK6cMWlsTKKyYO79KhRdky0mbp4FIJ5GBOCfXSMocLsfqpjdurqt-RGaPZLmUK5fUNFjHInoStgEK_t62uBYarKGtT-eAWEf5JJpirUkWaXFBHQw-zPpBzWAMsyqAvoIL0X8aKbrl2K21y3_srPhHqj8piyxpyN_6xhvy8_N5K1OHKyskdJLI8jBVLZjTaUvEPRjDgwLDMaP4gXP2ktHlCBZp-yxs7Cj9HfHmtibRaNjYkrqR_Uw5uTQpTxZ8wTDcrwHHKuX8YyiwirJvrFGyppJhvEN1aN_0jfx-qV0UwG2LkEkeYOYcTSqTS2dyZvh7s5oRVwQ9DFK6Ye4-PaBCE8jjmD9_ayXxwWFCh7Bmk8GWEDET38fpLgjME_M9ppq4Skbj9tSCWlh-JVwxGFYG-qFb5ZdeF0APVaLmY3j19cA6NfUvqaJX4zJdJ7az_aFiEhKU-C872G31U0d-mWHxW1FJUsA2jtw1EbZ_DH1ONgeKBLSQHWhc6DW9eovrvP6jFClzLwocKb1ZyXGfZgAeWgRwvq8MOvNGb1YYMuVZBgHvTRZjG-wxvlZvKk7gmiFrFf82gFbM0IOrp_TUx-Tw1W6uJM4Nj1I2QHcZ8dq9HNbkxkidlyYNp63Z2V9YgyaDKIebSpnHMSTNFJHvqb6jVXOYMJaQrFTBzaC-iNoVkNXKPocoWYxtyWMHkWoplFiMvKRjd9v-REDdSn05_-_8CYJxIShI9DTAf1E0h2Q8fBIvQ7u5_lCcwywFRKx3ttpdGBTV5vv4wRXirY4GU306deHPNE8OCv7HPty0qzeSjfdfz1NXD-I57Ehwm3w1FnQ48vg03HZQMjg57jxvQCCfRci3GkYybgf4qF1U--Ou1WyRowxcg3bF9dE1Jw5jXjYOfIyZw3EhTJMGizcOIdbx8BkbSl07aonB9a6VUKyDJG3wioBXBzFFHRgaTBcKP9vx8x4ikMXgQHj8ujgJXTtO3DmTOhJAdnNSOlXui62r2oDziCkJJal-IopQY6dMCdy60cmd-fA-AnFCY5vC8PGSHNB4QCLPjKMCR-f2XAYUV5EqK1C4l8ttLC6sTTHvjAaA5Zs9jBUzYd4LYf5_6m0GbQEuu47TowjIYKb6l91lsiArwtVAx5XOR3ReNfzg8pbv_KmJlc57b2NDqSubzE-AB8zhF5wyaEtqCyHBX9q-6QHcmRd-0zfPbYvkHlB4Ql6enNa0buZ5GGXFlJfYcfA5xM-r6u0ibaZdpAVPUEw0p11iW6_t3IQOM5eWMUbtg-5weSY9ufqorZobYUSj39AE7OjhHUhoColUq3inzqT6mt93IMwbmw8YNok470LzHQnJUYslECzKu-GweRxfs4Csmaa50VLrr2zK95S64k8DOvPcxL1TqmxnuabVgtusgNTLmBrZZRw1hIzDCYIvKZZJoZo-JQ21Xc4H64bpUVzyn4GBwZtfXdVYn3WMigKnSNXgbJbXP49zDsqz8vIK5vYh__0rj_ByooIGi_X8rBv4fdqTivDAeVii0P3vwgqoi4SP8xyFhg4ZfHKuAOfn0YNC3xCuhEp46LBPvYNrXrqdXhAtTkr49HipOpSC93xW_CyrdFCk8Lpopc1JshtuAvF4ZMe_qZiuCT1gLTRerStoSzIcaTO7061Owo-ySUBEF3TKZtkv9n8no2n8CzCoIzcgN4MfTshQyrdiY5rWqVPVRgEP6TQqCaeTcz1FXWK_UreuDWN4APLKK11sNQVTAIHcZUxwtPl2tJYOTBn0suR98Ero40Ig_kc-4xD4cn8k5p7qXqKC3lBUPrqnxytV7dHfzAzW4pqLucHtMXge6Oj17ko_He7VSFkgvOERc_i3LD9ONZGpssy-A6qTvpKs2_SQ12pTkRxuh7lB8Y0kbfTZYXsvosSVzj_bndqil5yE2BOmL4C1l-bNrZC1FCmDEIvT-x-cC14pELqxCwe9D_ngsx0N_FXs8sNJpq0WXk1v28-JYpwpC6EO5luCaDQzqtbDPGR5-9aNOy3d8ItbfxLP1OnR2wOB_Iy4h6enrNBnmTqgbD_dl53me_mhOeshKEIFo5FFGX518ezx0j4zYq_ID_kU2RUe0r82goCsAhrHS6KbMr8JHks-Pkr3KK0COlFAlba2aiR5PbV2h0Iang8wm3MIc7iMDoo2Ai5NBQoR_PUbJrLAGsFbyFXzMkP9vdFS1RsuLILYIOYGkUrOuNYPdnVfcYsKwW-HBTllRQhdXNoi-UzhWIUGWHtm-KMH3VvH5dUnEvSZdmWqONKLxrqsNykO3xe2acaDCl1KEdvGJoRUAFxAv065ZIzNDGsL-GXLw6QkS49FC_EHBNrXQ5pQAhf4-u82EuwyrZDpkkfn7i73jWQM0_2lwVqeOxqbQaQq0P7oXUOSpF36D8MmiV9mdO2W2-HnVyPuL5M_3fSdxeAc7ycjznxk0nHpYje1c1hFMFRPYAp316hfPEJypxZybbt2plz77ZJrTMC1KBAcbkARHHNCd6HnwdLi6hpF7M4iwczSGp1-QNw_KX1uX0jE2MDKKrKj25kajbBICxrdCEwYwDVGU8Z0K-QgmPo8QYwnNWc",
                "code_execution_result": null,
                "executable_code": null,
                "function_call": null,
                "function_response": null,
                "text": "Analysis Results\nCase Analysis: Relapsed/Refractory KMT2A::MLLT3, NRAS-mutant Pediatric AML\n1. Case Summary\nThis report concerns a 4-year-old female with *KMT2A*-rearranged (KMT2A::MLLT3) acute myeloid leukemia (AML), initially presenting with CNS2 involvement. The disease has demonstrated a highly refractory nature, failing to respond adequately to induction chemotherapy (NOPHO DBH AML 2012) and multiple salvage regimens. A first cord blood hematopoietic stem cell transplant (HSCT) was performed, but the patient relapsed 10 months later with femoral extramedullary disease. Molecular analysis at that time revealed a co-occurring *NRAS* Q61K mutation.\n\nThe patient was subsequently enrolled in a clinical trial with the menin inhibitor revumenib (SNDX5613), achieving a significant molecular response. This was followed by a second allogeneic HSCT with revumenib maintenance. However, 6.5 months post-transplant, she experienced a frank bone marrow relapse with 33% blasts while on revumenib. The current blast population is positive for CD33 and CD123. The case represents a significant clinical challenge of multiply relapsed pediatric AML with acquired resistance to targeted menin inhibitor therapy, likely driven by the *NRAS* mutation.\n\n2. Actionable Events Analysis\n| EventType | Genetic/Clinical | Explanation | Targetable | Prognostic Value |\n| :--- | :--- | :--- | :--- | :--- |\n| **KMT2A::MLLT3 fusion** | Genetic | Primary oncogenic driver of leukemia. | Yes, with Menin inhibitors (e.g., revumenib, ziftomenib). | High-risk marker, associated with aggressive disease and poor outcomes. |\n| **NRAS (p.Gln61Lys) mutation** | Genetic | Activating mutation in the Ras/MAPK signaling pathway. Known mechanism of resistance to menin inhibitors. | Yes, with MEK inhibitors (e.g., trametinib). | Negative. Confers resistance to targeted therapy and promotes proliferation. |\n| **Relapse on Revumenib** | Clinical | Disease progression despite treatment with a menin inhibitor, indicating functional resistance. | Yes, by combining revumenib with an agent that bypasses or targets the resistance mechanism (e.g., MEK inhibitor). | Poor. Indicates aggressive biology and exhaustion of a key therapeutic class as monotherapy. |\n| **CD33 Expression** | Clinical (Immunophenotype) | Surface antigen present on myeloblasts. | Yes, with antibody-drug conjugates (e.g., gemtuzumab ozogamicin). | Therapeutic target, but not a strong prognostic marker on its own. |\n| **CD123 Expression** | Clinical (Immunophenotype) | IL-3 receptor alpha chain, highly expressed on leukemic stem cells in AML. | Yes, with targeted agents (e.g., tagraxofusp) or cellular therapies (CAR-T) in clinical trials. | Negative. Associated with poor prognosis and leukemic stem cell burden. |\n\n<br>\n\n**Interpretation:**\nThe constellation of findings defines a highly aggressive leukemia driven by the *KMT2A::MLLT3* fusion. The presence and selection of the *NRAS* Q61K clone during menin inhibitor therapy is a classic example of acquired resistance through activation of a parallel signaling pathway. This renders menin inhibitor monotherapy ineffective. The patient's relapse on revumenib is the clinical confirmation of this resistance mechanism. Therefore, any future therapeutic strategy must address both the primary KMT2A driver and the *NRAS*-mediated resistance pathway simultaneously. The expression of CD33 and CD123 provides additional, independent therapeutic targets that can be exploited for cytoreduction or as part of a combination regimen. The pending WES/RNAseq from the current relapse is critical to rule out additional resistance mechanisms, such as acquired *MEN1* mutations.\n\n3. Treatment Options\n| Event | Treatment | Evidence | Evidence Summary | Previous Response | Warnings |\n| :--- | :--- | :--- | :--- | :--- | :--- |\n| **KMT2A::MLLT3 fusion** | Revumenib (Re-challenge) | [Gandhi et al., 2024, ASH](https://ash.confex.com/ash/2023/webprogram/Paper180862.html) | Initial trials showed high response rates in *KMT2A*r AML. | Initial MRD response, but subsequent relapse on therapy. | **Insufficient as monotherapy.** Relapse indicates established resistance. |\n| **NRAS Q61K mutation** | Trametinib (Monotherapy) | [Borthakur et al., 2016 [PMID: 26864227]](https://pubmed.ncbi.nlm.nih.gov/26864227/) | MEK inhibitors have shown very limited single-agent activity in AML. | None. | Low efficacy as a single agent. Potential for dermatologic, ocular, and cardiac toxicity. |\n| **CD33 Expression** | Gemtuzumab Ozogamicin | [Kadia et al., 2022 [PMID: 35084478]](https://pubmed.ncbi.nlm.nih.gov/35084478/) | Effective in a subset of relapsed/refractory AML. Can be combined with other agents. | Partial response with FLAG-Mylotarg regimen. | Hepatotoxicity (VOD/SOS), myelosuppression. Risk is elevated post-HSCT. |\n| **CD123 Expression**| Tagraxofusp / CD123-targeted trial | [Pemmaraju et al., 2022 [PMID: 35696357]](https://pubmed.ncbi.nlm.nih.gov/35696357/) | Tagraxofusp has shown activity in CD123+ AML. Novel CD123 CAR-T and ADCs are in clinical trials. | None. | Capillary leak syndrome (CLS), hepatotoxicity, thrombocytopenia. Requires specialized monitoring. |\n\n<br>\n\n**Clinical Perspective:**\nGiven the relapse on revumenib, re-challenging with any menin inhibitor as a single agent is not a viable strategy. Similarly, MEK inhibitor monotherapy has demonstrated minimal efficacy in AML. The most rational path forward involves combination therapy aimed at inducing a deep remission to allow for a potential third cellular therapy intervention (e.g., HSCT or CAR-T). Targeting the surface antigens CD33 or CD123 with agents like gemtuzumab ozogamicin or through a clinical trial could serve as a valuable cytoreductive or bridging strategy, but it is unlikely to be curative alone in this setting. The risk of VOD/SOS with gemtuzumab is particularly high in a patient who has received two prior HSCTs and thiotepa/treosulfan conditioning.\n\n4. Multi-Target Opportunities\n| Treatment Combination | Targeted Events | Evidence | Summary |\n| :--- | :--- | :--- | :--- |\n| **Revumenib + Trametinib** | *KMT2A::MLLT3* and *NRAS* Q61K | Preclinical data; AUGMENT-101 Cohort K (NCT05028962) | This is the most rationally designed combination for this patient. Preclinical models show strong synergy. The combination is being formally studied in a dedicated cohort for patients with *KMT2A*r AML and *RAS* pathway mutations who have relapsed on menin inhibitor monotherapy. |\n| **Revumenib + Venetoclax** | *KMT2A::MLLT3* and BCL2 Dependency | [Kloss et al., 2024 [PMID: 38241416]](https://pubmed.ncbi.nlm.nih.gov/38241416/) | Strong preclinical evidence shows that combining menin inhibition with BCL2 inhibition is highly synergistic in *KMT2A*r AML, overcoming resistance. This combination is under clinical investigation. |\n| **Azacitidine + Venetoclax + Trametinib** | BCL2 Dependency and *NRAS* Q61K | [Pollyea et al., 2022 [PMID: 36585566]](https://pubmed.ncbi.nlm.nih.gov/36585566/) | This triplet has been explored in clinical trials for *RAS*-mutated AML, showing promising response rates by simultaneously targeting two critical survival pathways. It avoids re-using the likely ineffective menin inhibitor. |\n\n<br>\n\n**Analysis:**\nThe most promising strategy for this patient is to directly counteract the identified resistance mechanism. The combination of **revumenib and a MEK inhibitor like trametinib** is supported by strong preclinical rationale and is being investigated in the AUGMENT-101 clinical trial, which represents the most tailored therapeutic approach available. This combination directly targets both the foundational KMT2A dependency and the NRAS-driven escape pathway.\n\nShould this not be feasible, combining revumenib with venetoclax is another evidence-based option that targets a different, synergistic pathway (BCL2) known to be crucial for *KMT2A*r AML survival. A triplet combination of azacitidine, venetoclax, and trametinib is also a rational choice, addressing the *NRAS* mutation and BCL2 dependency without re-challenging with a menin inhibitor, which may be beneficial if a *MEN1* mutation is discovered in the pending relapse analysis. The ultimate goal of any of these salvage regimens would be to achieve a deep molecular remission, enabling a bridge to a potentially curative cellular therapy.\n\n***\n\n**Disclaimer:** This report is for informational and research purposes only and is not a substitute for professional medical advice. The information provided is based on the data supplied and a review of publicly available medical literature. All treatment decisions must be made by a qualified multidisciplinary tumor board and the treating clinician, taking into account the full clinical context of the patient."
              }
            ],
            "role": null
          },
          "intermediate_data": {
            "tool_uses": [
              {
                "id": "adk-ff6b7cb3-c366-4cc9-83e0-a728c99eb385",
                "args": {
                  "request": "A 4-year-old female with KMT2A::MLLT3 and NRAS Q61K mutant AML has relapsed through two hematopoietic stem cell transplants and revumenib therapy. The current relapse shows 33% blasts and is CD33+ and CD123+. I need literature on the following topics:\n1. Mechanisms of resistance to menin inhibitors (like revumenib) in KMT2A-rearranged AML, specifically focusing on the role of co-occurring NRAS mutations.\n2. Clinical and preclinical data on combination therapies for KMT2A-rearranged AML, particularly menin inhibitors combined with MEK inhibitors (e.g., revumenib + trametinib) or other signaling pathway inhibitors.\n3. Efficacy of CD33-targeted therapies (like gemtuzumab ozogamicin) and CD123-targeted therapies (like tagraxofusp or others in clinical trials) in relapsed/refractory KMT2A-rearranged AML, especially post-menin inhibitor failure.\n4. Emerging therapeutic strategies for pediatric AML relapsing after multiple lines of therapy, including multiple HSCTs and targeted agents."
                },
                "name": "literature_review_coordinator"
              }
            ],
            "intermediate_responses": [
              [
                "capricorn_medical_oncology_agent",
                [
                  {
                    "video_metadata": null,
                    "thought": null,
                    "inline_data": null,
                    "file_data": null,
                    "thought_signature": "Cs0nAVSoXO74VzG-5KkU9SCPihN9eMR82ewbPotOHe_rujzJiOsS9wXBihpQ4EEZTwqFde34dxPdKKg9zLwpRueQ4SkSq4qZWXxqa5hMmU_RzNDrC5uxSDjm_IicQKVDaKobQqMpKVdU5SnJ1qfEtdBI9GbOtL3DtqVvn5iwff13QhflswBr3m2efS3gn_roIoaWyq3mRfIRW7HWMTZlYnGSk-7fVQHpZ4MCaRfnXjnB5XjqZhdH8T5Jfs1yP45WtfjQWHIIuzcHdKTgC77On3hZSAy4kX6qumDk5GlM06KvX5gkRV_vl5IazSDi_0AGlvQ52Bnji8YpI4zpjDgrnSYs1SPvVthzF2VXRrS0kscCVXd-EoUInjU7S0u7DdzUiV6FSit6g8G8UJ2_JzqZCJNxJXIG5EbsBQ79rEUDPqFBPwUrqu4QCTENWgWxwqjKaxx_j9Wy831ZSMGibYgQRym7trPHS0sN0RIOVmHbsuEar41c7aoenmpsngmRmCH6hW7b3jWEJWUEQ7OBZkgwA-vb-VXuKzM-W5QuxmZ1Z9eP31gEOCcb19jNCpV5JW-bahUe12ZEc90v-k2X1ZcGNZ-DWWjlo5TXIGKPPIz3Tosg_YYOGV1TouZYiWlrtp1YlxsJ7OMB3PUHlrN3OvaGDc_xZe07JTJOlF-ewT07H0xUsdSuqhLBd0y3V3TCHUJ61Y1JhztrfCzdgy8jbPiJCi4pryab9gk-oyu5nJTqpLocLhKq8yF61jtEBbu6qotbilOTSUNrWjt2foslFKVB5YxjG8XOzWk4tNAGPRJQcI2Y2owtC2ha4eMTlAC6lvJW6xpDmfgA9RTps5jGrJQJtNJYMEMNCwttsVehZKaizxpVKIMWM5WMbZLZTaq0yzNQX6ArrFqYnnhIn53mnNBDMBR378ePgKPZwlvuSEy0A3xjmYKLBdu6xNisvgcYOvRR021FugWhrVs2fkMswQcx2YxPEIluA9Zlhk6hodqvDMOFnw4X4JfyZaKUo6WCCSqvOWjU82kX2oTvCrY6vqmrIJcYZGiJqDF2MBOctfpXvX4L0-ABTyjBpYdU7iYx76lvKcSMlye2bL51YKfUMTjqXGPCX70MfqgrPYJlZIGrpMcnq8bhDPPbwcBcH-mviGujPDQ2L_4bjqTKRdYuOZFs7WbtJwRjdl13_XLJZ31ITmMSNAlqYyHg3WFyWl7y72pOlnypCYib6Uz4lvol0UZ7k8MpwnoWUtfyy0NghIlneQeXXKrIRgeJSK-9hxsg2uRRBmrBy6EuJ40uu9H7Fz1OB4LopJyfwNdLGNdh_3R4ogNxkLlgw39c54q2-ZOWffL_0dNOe0FwaWm_ManzCcuinaIim2JJm_6i6-4mHnaLHW5otVE4KLl0eeEIyNG1e65-9m8s53MDOYZOv5-5LfBcB1qKTUE8zI5iB8JCyD1MoGCEAULUN5X5yaxjlOXx-KqnjGIOpKScA_8P6a4ZDPionYWlUAb2ZHlDYdVkG2zYqvCYyXwtiey7R9-Azd-qquOdq3VM7F1OrTswC2qPCbJoGyvz-nxNQ6ZBnlvlprBoDj6XS3TGLyM_jLEJj8TRXmxCMWKeLxIqnPgoFdygRIV1cdFChXKZ-MnK7TM5sA4aMjA5LUb1b-VC1kGpWNx7T1Vq30l6ncMMdQB-d5jmcQpkX4ySzqPayRsdsrTUC59UlW-eZtAnKtX34rcCKe--RUkZhYon8Qzogu_iMiAIT6BSCYpN_RpFYdH6ibfZhAgdy29lIzCoGPlmIpZSSqMwAnXJGE-90X5dWWbumRKCo0-Y4DQf8eDPDgVzjbuOv01cDQA9QiFhf6ZPi0e2j_GM4bCvXVvkzrWVKSDN9cOYBm-YaPO-CZ_UFq7O_Bw3bapyCtFqau5u3-jTy8_8fLS6-2aBwHDG7Y5Qg_Y3pZlkEF0rJdQ3Hpknv7qDNJgFaKOS9fX6fZjvnvBT5KlUdJ4tcZpyLINoBhTB0xqpsdkUnRyDOTRHmyTJr07Y4YuBojycc3ZVRL1D7nEq5BP7GZz2A1qlFt3Q1GQ4g8zeIyOAHUVaJmKQUc2XQWMCqada5ykBP6ubEueV7F3wVJFWpXksRjzA20_LY04IzmSG3_WhiIovzeiNUoVGkeW9MrrTQgcUvnZy3MUyg1413v-bioFLGzTVVKrh3XN8rEHILDCtcUl1fDu9BtoiZNUo9lAUc43Hdn7Zpmwi6pvXZ4Xo3RX7XP1cBkYvYuoycIDMknupqoIVoObLSiHkOvETdnAP8UD1F5avZCdLwXRP38szB0-skpvBnsY4CDJN5dTOVsY96e1vI0m8TRZkExSoEaS_X2fI5fb7Tcp7JPVmVAJPyjhMd2zFAUztOkSydEs8l72ddDtG4x_c6_MAgL8q4qyyvZYrIaKRYTq9eoLtg51gwIlGTpnWlKKrfXX_keSeJxZNCOXgeLglF3_jXRsZg5QL-SKL6Pt8qRDrM-uUNW3oL3eXV4rgCxIGjYJL8hNEkgpi5JIfZME_DDYLK6cYiwQT4kQQYE9TSWxEeFDH_ixb02CQicSEProPbbxLP8ImjVUvLTObjXWDhLafPf9ikbK7FzKnPfYZwsNhXcdug3EPnR3asE3uPn_Cx4vvK7zVTp9i67wfVfEaJT8fhV3WJcSRXfaPmQedhCG64DwEhusSQk4QstqjkFFftVLvnLZOvCyn0BHQBQ4-E5ULkxKe1ZPaFlbuJ44tzOJ_X19-qOyb78mh3U1VU9rBrRXPorkEwUN5j0trTdfQKHaegbrRhg_Si4DT1cpbR86eaozNHtzkJFApMk5rpzb5laMt29hO7NRfNDXlyAo3K5n150KaSdifQ8SdeGdSBml11xojlspnv92v7VG573VTCdc_K4-oep_xQoF25mf2wsRkp5HFFGkgKhRfsTMnAPUMRp_tmFhNRFGKM2aVYacN0U6037DKMrneaGdpLGI20jyp__ftJnzStXqVm_5jQtQGE0Qbs_xfyddmasniA6uD43lzu2zJZ9iYPZ4JvUPwjUIKBP5pibeb7zK7olEk7xfwvN2YGSAei6UffdQuUTiz91f5cH8YPj2ERuzeDZTI-ghHHvQq13-kO3TOMKGxQDyZgZ5dBLnPwCf0PLSn9p4ERiMZb4fsJj_3N0cZ57tzMABu64U6WCjAWpb0sVCOVQ7kX2D1lS-7qGM2iwQ4BaTyYQnNumvrDM5aiN-e0BRb06Y2bdobO3ffDZ3WkYviWboDy1sfP-PLPaMBIIAWYN3YPLnFRLB50rBmqxs26kKfiumBqsOUQcgeSxAm_TAIp0EjdM0jOngnkQ3UT_fByJ7NKtYRqxJeQ2kGLX49uXZVsi7XC_J6N_zPP4U0Me94hYWB32Ltz2jQl8oBJkaOM_Xjly6f8NFmgXlTGPB42_jC0LSIC17cx19dj6KWCbwwNNZV2vQKH3xFqVou09SyRaoj9p7qbLVcLLR5c7jY9gPTOLD8xvfFhbf-BzCX4uTUvC51nsG4JRaNI_KL1eprn2Q6vmH917-Ijm4iYjtgWKhrGLxbXt5bFPMYYsaNWnNYqE3GUPlrycjWLK1AKi_GgHwSbq9BCkTVhHw1ezvj4kYV3rmdly-VPZA1y2_M4SH2JE1zU1QFNn1W8mHqFdGMCl6wNoAQ05_gT4hQZhbafeT4la0QZHdHqUEDxSKEJ7Fdt_XvAj_j4zmJ4GVn0nYR9VflxTpH_yfgF8kbtZPMB5m10XWtgW9msiudOCj6JFFaUibBETPFZDBamCV6rnxtUaIZzxFhQ1l0lKtO1czNyChiFGE7bJj6B65RZKtdtho5sFT-r40-5kYqm6HmETMR1k_zdUtL7Hlu5aU7DjrxwI-oJljUprNl3Bs0FlOQFOLQPmFKizc9kbRIhiGUvZd3cdbpNaVY_oNos4HQWz9621300mK2UR9DUE3tzlbG-iIymPlk9ThRFt1ezJZ0lreH1hHsNzYTt2QlWQ8uF9nHZxXtuncUStizvhoAgQ80jtFLg7TT8ghMGa0eUQbFhGNa80D4UYIuufRTK_H1V5iWUQv0QlFdvxO6MHItZdCiXfxY5N5RxTCm-9x6byyJh18R7Wtb1zWA9FqYIu_bkXg8W0k5UaiMG_aWk6I1kjyXtd7YBQLID8spygdAF83NF7PUAm9bmdYVKyNuuFvS-bFjB3a0xZRObF2EiBCU4YO9x9kajgYq9Ya1ZK7dqE5u-oR-t-S-6c7ykoutieJZ04M-S7HZp3Khq1qDA6DgDxqQY12BUbjDXiTaGyLhuSYO6W9EGSPVJsFsLWp_r__CysNAAaOn8Vp88Ko-15wFWL_VoNX_7P0jfpZxVkIoWJ7id3OZ1fFlmGxchNcS5ONYlnMsTvhF72dr2SLL6UUUd_miKx9nULqP2Urp0qkM39vyGekSHLqSAH4oaWZdXZj6vfdxsjwq9TGxyB7kahBfj-0h1ItAZHCda3BZFUNulllyKqXLgELBy9KbwyBdnbNLb-C0QO5p8ldWY_GBfWu6LBaCXJWg0YKfdaqyA_fdGknK_vpgBetuI85zu7XaqDrKxEoi2FUENSAXte44zKgEcZ2pyCjDsHhB2qIk9O7XrOiJ-OqGk6T6L_zLz6B0ytgzffEaqSxFoOmANkSDN63Je93nxf7Cx4Nin_Nj06sF9AEanWneQ6mnvoj0zwIwgOd5qBhC9TO4_z7QNVK4qjBLQ_hn5XyMkaiKERlwH-ZyuB2RXYbM_INd-6xiOspCIK8AYMT8kadJDupD2EkLSlVfBPX2_Mn0v9PueSEIUR5em6-ysH9TIu1xwwodEZNb--x5viV5OUw5aCB_7HuE1EVHgGxX2FQQUuCbhUg53M2GfgrPu-Fxcg0Y8kaesX09WMizJegee8FmnIKKzOoA2j44C6slmxCwhTWg3OoAAD9EJkDLDR992pJdngCyF40MdRZOzk7UlXZWbTiII842op5U6c5HohTZQgozqwvU0yzOujzcOUQW23Or353r0wGjESrt1ujon1gvYDrdNpACWTTXqTQ7ey6Vf6MT7wvNNuQ3gSQs1S1oj2QiCxKn5Jvxh-cT6EJRp-RFZFkryf041VS_WITQ7l61JfzRckywbrkK5R4LZmgWt0M3ay-QM9tfdW5imCOcuIvCbyFX7Oa_a6myQN31LT-WPcHT-7rUoHQZ9GRqYLkHKILJlWd__62R5-XIzvKGhzcfKmfT1aC5H1_PMlC26Q7-w88lQl-dwIumhQXUdq_L0lLoICwb7kyopkkRJ2_U2WR-8dU-DosMcthxgyIdAcg5DI_AcLLdhT6UhwqUi0tn3NcS29NMBUuhVugFLdBU15bmBHCKRtvov17TTJwHCRDIm2L6Qu0NDgDBUf8F0g6QUu959T5lBd6QImNdSUu8EOctY1y6IXh4-s1crFf05bfl_TRVt_wNnvy-IpJeM3yqkFHEVjkIC35nCi33Oz2EHidmAppI-93ZYsDzI-KnMICJTDLJzPZfjvgXUB61XFiCwMHfLo4H1D3IUIOGuLyONVoJ4WfFeXPRjgTmliZqNKq7zwRJwD6wCZlpMaF4TcpHWHbD3i-9bKJvzH-uAvNrjDXtZ1f3k63hcTrv67MnJQPXGhPo7LLjHMEBiBx-EpUI9A3hAcwKsZKO_MRt-AZlX2_Oww2XYaBufpjmQayQ9R6SfbMi2LT2Ih1ZqUWX9cUQXRhu4e_32KNHFsal4iuXkHWy8s5SIvZeYzRX7663EfNI8osoU64iKkZtQsbwlwd7K2CoHgeiBjtjlb4NPDBrpehqYJuRW6gw3uy4CUP6ZPZFKrMS1hlmfUoT54fY6YdbnnOQetLN69OD1yKod02nOBaomS41CTCtxU_Q3iJL3d-YaUsI8fMPaZmLlieQNcziHcZvbzt9wC56gIws7DtlQH3RTZENt8smDQQh63bZP8avOwCl8nztjtm-FMi_zgxrS_HnMl9XQ7y83pylT-R--rhmB0GoBSGJcRtl1shtrZJ2F66V1PZhD6-OSHnJzd6NBYaawnavQEQt4lRDNJsrqIr3FwcXmEmzeYdcStriOkTgHVi5uvZuYtY5rBOXH-dfb3ACThbKAuYcyUpF76S9I6eilQIw9H29o14S75U2exhgZ0GqBmuGuCJBXhdi9PDihngFey0QQ4gIbXLgo5brC0VDYRJnwdEiGGMud1BtGMyCxVhs8XMSSA-8kf5awL7EqzMUCgI3mTlbaIoZnKc-A_0tgn1iQhzOKc5O-fVYxHyA5tXLLF_FRQoZbRtIPk5UBAzdvFCttOYgkBscUbXMUD0qIyniz65kdp3tEFIZWtvckbz8WlbeT4_XngDKqWLvOTCvoDQR0bNPUXCIk3zJkEVcL_K1o26Q_PC4yiB4xfMBwn2xspv3vNmvuG3fJi-TOWf9-Yy33hc8EYCxB9ezU8_4d5ekmkLVV6kErVUUKl6VCdPCCoBBTH1g8Z0VOh-BZ_zZxkHs0WESixF3Wd3iNV4Ea6nXi4bNbaq8lJko3BNOUdWRn2MWPZsbXGMYvs-5roYgLNFCKGSOhLXrHWKZLIL8GEfZ955WHwyuDmwzbHMX5c4LCXlBXDZtSAqV26zUUlDI0SJCA8d0kD209fOy9dSSFsSnZWvvjeLq775r9VM4l9S8SCp33Y2QISeo5Dcix_Zy87GPrnmWRi5jVTt9V1enwyOVWdPJ2Fs7r1WJrGpgjdjativxcB5NcGGXXd6837izZ0l-DiM44oONYZjwHTj65yR0ndDc-wTTLyjHKzM=",
                    "code_execution_result": null,
                    "executable_code": null,
                    "function_call": null,
                    "function_response": null,
                    "text": "Vetting and reviewing the provided information for the following Case Report.\nThe user wants me to act as a Clinical Oncology Decision Support agent.\nI need to analyze the provided patient case and generate a structured, evidence-based report.\n\n**Patient Information:**\n- **Age:** ~4 years old female\n- **Diagnosis:** KMT2A-rearranged AML, CNS2 involvement at diagnosis. Currently in 2nd relapse.\n- **Molecular Profile (1st Relapse):** KMT2A::MLLT3 fusion, NRAS (p.Gln61Lys) mutation.\n- **Molecular Profile (Current Relapse):** WES/RNAseq pending.\n- **Immunophenotype (Current Relapse):** CD33+, CD123+.\n- **Treatment History:**\n    1. Refractory to NOPHO DBH AML 2012.\n    2. Refractory to MEC and ADE.\n    3. Partial response to Vyxeos-clofarabine.\n    4. Partial response to FLAG-Mylotarg.\n    5. First HSCT (cord blood) in Dec 2022.\n    6. Relapsed Oct 2023 (1st relapse).\n    7. Enrolled in SNDX5613 (revumenib) trial, achieved MRD 0.1%.\n    8. Second HSCT (cord blood) with revumenib maintenance.\n    9. Relapsed Aug 2024 (2nd relapse) with 33% blasts while on revumenib.\n\n**My Plan:**\n1.  **Initiate Literature Review:** The case is complex, involving relapse on a novel targeted therapy (revumenib) with a known resistance mutation (*NRAS*). This requires the most current evidence. I will search for literature on:\n    - Menin inhibitor resistance mechanisms, especially involving *RAS* mutations.\n    - Combination strategies to overcome this resistance (e.g., menin + MEK inhibitor).\n    - Options for targeting CD33 and CD123 in this context.\n    - General strategies for multiply relapsed pediatric AML post-HSCT and targeted therapy.\n2.  **Structure the Report:** Once the literature review is complete, I will generate the report following the specified markdown structure.\n    - **Case Summary:** Briefly describe the patient's journey.\n    - **Actionable Events Analysis:** Detail the significance of *KMT2A::MLLT3*, *NRAS* mutation, CD33/CD123 expression, and clinical relapse on revumenib.\n    - **Treatment Options:** Discuss single-agent strategies. This will be challenging given the patient's history. Options will likely include re-evaluating CD33/CD123 targeting or considering alternative agents.\n    - **Multi-Target Opportunities:** This will be the core of the recommendation. The combination of a menin inhibitor and a MEK inhibitor is a strong theoretical and evidence-based approach here. I will also consider other combinations based on the literature review results.\n    - **References:** Compile all citations.\n    - **Disclaimer:** Add the mandatory disclaimer.\n\nI will now call the `literature_review_coordinator` to gather the necessary evidence."
                  }
                ]
              ]
            ]
          },
          "creation_timestamp": 1754696858.113138
        }
      ],
      "session_input": {
        "app_name": "capricorn_adk_agent",
        "user_id": "user",
        "state": {}
      },
      "creation_timestamp": 1754697372.625907
    }
  ],
  "creation_timestamp": 1754690949.879141
}